TY - JOUR
T1 - Association of N-Terminal Pro-Brain Natriuretic Peptide Concentration in Early Pregnancy with Development of Hypertensive Disorders of Pregnancy and Future Hypertension
AU - Hauspurg, Alisse
AU - Marsh, Derek J.
AU - McNeil, Rebecca B.
AU - Bairey Merz, C. Noel
AU - Greenland, Philip
AU - Straub, Adam C.
AU - Rouse, Caroline E.
AU - Grobman, William A.
AU - Pemberton, Victoria L.
AU - Silver, Robert M.
AU - Chen, Yii Der Ida
AU - Mercer, Brian M.
AU - Levine, Lisa D.
AU - Hameed, Afshan
AU - Hoffman, Matthew K.
AU - Simhan, Hyagriv N.
AU - Catov, Janet M.
N1 - Funding Information:
Funding/Support: This work was supported by National Institutes of Health/Office of Research on Women’s Health Building Interdisciplinary Research Careers in Women’s Health grant K12HD043441 and by cooperative agreement funding from the National Heart, Lung, and Blood Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grants U10-HL11999, U10-HL119989, U10-HL120034, U10-HL119990, U10-HL120006, U10-HL119992, U10-HL120019, U10-HL119993, U10-HL120018, and U01HL145358). The study was also supported by grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grants U10 HD063036, U10 HD063072, U10 HD063047, U10 HD063037, U10 HD063041, U10 HD063020, U10 HD063046, U10 HD063048, and U10 HD063053). Support was also provided by the National Institutes of Health Office of Research on Women’s Health through grant U10-HL119991; the Office of Behavioral and Social Sciences Research through grants U10-HL119991 and U10-HL119992; and the National Center for Advancing Translational Sciences through grants UL-1-TR000124, UL-1-TR000153, UL-1-TR000439, and UL-1-TR001108; as well as the Barbra Streisand Women’s Cardiovascular Research and Education Program and the Erika J. Glazer Women’s Heart Research Initiative.
Funding Information:
Dr Greenland has received grants from National Institutes of Health and American Heart Association. Drs Silver, Chen, Hoffman, and Simhan have received grants from the National Institutes of Health. No other disclosures were reported.
Funding Information:
Catov have received grants from the University of Pittsburgh. Drs Marsh, McNeil, and Mercer have received grants from the National Heart, Lung, and Blood Institute. Dr Bairey Merz has received personal fees from Abbott Laboratories and Sanofi and serves on the board of directors for IRhythm.
Publisher Copyright:
© 2022 American Medical Association. All rights reserved.
PY - 2022/3
Y1 - 2022/3
N2 - Importance: Hypertensive disorders of pregnancy are associated with future cardiovascular disease, perhaps because of subclinical cardiac dysfunction before pregnancy leading to impaired adaptation to pregnancy. Natriuretic peptides are promising biomarkers for detecting subclinical cardiac dysfunction outside of pregnancy. Objective: To investigate whether higher concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) in early pregnancy would be associated with hypertensive disorders of pregnancy and hypertension 2 to 7 years post partum. Design, Setting, and Participants: This cohort study used data from the The Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be Heart Health Study, a prospective multicenter observational study. A total of 4103 nulliparous women with complete data and no prepregnancy hypertension or diabetes who were treated at 8 clinical sites were included. Women were followed up with for 2 to 7 years after pregnancy. Data were collected from October 2010 to October 2017, and data were analyzed from August 2020 to November 2021. Exposures: NT-proBNP concentration, measured using an electrochemiluminescence immunoassay from a first-trimester blood sample. Main Outcomes and Measures: Hypertensive disorders of pregnancy and incident hypertension (systolic blood pressure of 130 mm Hg or diastolic blood pressure of 80 mm Hg or use of antihypertensive agents) at follow-up visit. Results: A total of 4103 women met inclusion criteria; the mean (SD) age was 27.0 (5.6) years. Among these women, 909 (22.2%) had an adverse pregnancy outcome, and 817 (19.9%) had hypertension at the follow-up visit. Higher NT-proBNP concentrations were associated with a lower risk of hypertensive disorders of pregnancy (adjusted odds ratio per doubling, 0.81; 95% CI, 0.73-0.91), which persisted after adjustment for age, self-reported race and ethnicity, early-pregnancy body mass index, smoking, and aspirin use. Similarly, higher NT-proBNP concentration in early pregnancy was also associated with a lower risk of incident hypertension 2 to 7 years after delivery (adjusted odds ratio per doubling, 0.84; 95% CI, 0.77-0.93), an association that persisted after controlling for confounders, including hypertensive disorders of pregnancy. Conclusions and Relevance: In this cohort study, higher NT-proBNP concentrations in early pregnancy were associated with a lower risk of hypertensive disorders of pregnancy and hypertension 2 to 7 years post partum. These findings suggest that normal early-pregnancy cardiovascular physiology, as assessed by NT-proBNP concentration, may provide biologic insights into both pregnancy outcome and cardiovascular disease risk.
AB - Importance: Hypertensive disorders of pregnancy are associated with future cardiovascular disease, perhaps because of subclinical cardiac dysfunction before pregnancy leading to impaired adaptation to pregnancy. Natriuretic peptides are promising biomarkers for detecting subclinical cardiac dysfunction outside of pregnancy. Objective: To investigate whether higher concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) in early pregnancy would be associated with hypertensive disorders of pregnancy and hypertension 2 to 7 years post partum. Design, Setting, and Participants: This cohort study used data from the The Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be Heart Health Study, a prospective multicenter observational study. A total of 4103 nulliparous women with complete data and no prepregnancy hypertension or diabetes who were treated at 8 clinical sites were included. Women were followed up with for 2 to 7 years after pregnancy. Data were collected from October 2010 to October 2017, and data were analyzed from August 2020 to November 2021. Exposures: NT-proBNP concentration, measured using an electrochemiluminescence immunoassay from a first-trimester blood sample. Main Outcomes and Measures: Hypertensive disorders of pregnancy and incident hypertension (systolic blood pressure of 130 mm Hg or diastolic blood pressure of 80 mm Hg or use of antihypertensive agents) at follow-up visit. Results: A total of 4103 women met inclusion criteria; the mean (SD) age was 27.0 (5.6) years. Among these women, 909 (22.2%) had an adverse pregnancy outcome, and 817 (19.9%) had hypertension at the follow-up visit. Higher NT-proBNP concentrations were associated with a lower risk of hypertensive disorders of pregnancy (adjusted odds ratio per doubling, 0.81; 95% CI, 0.73-0.91), which persisted after adjustment for age, self-reported race and ethnicity, early-pregnancy body mass index, smoking, and aspirin use. Similarly, higher NT-proBNP concentration in early pregnancy was also associated with a lower risk of incident hypertension 2 to 7 years after delivery (adjusted odds ratio per doubling, 0.84; 95% CI, 0.77-0.93), an association that persisted after controlling for confounders, including hypertensive disorders of pregnancy. Conclusions and Relevance: In this cohort study, higher NT-proBNP concentrations in early pregnancy were associated with a lower risk of hypertensive disorders of pregnancy and hypertension 2 to 7 years post partum. These findings suggest that normal early-pregnancy cardiovascular physiology, as assessed by NT-proBNP concentration, may provide biologic insights into both pregnancy outcome and cardiovascular disease risk.
UR - http://www.scopus.com/inward/record.url?scp=85123944635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123944635&partnerID=8YFLogxK
U2 - 10.1001/jamacardio.2021.5617
DO - 10.1001/jamacardio.2021.5617
M3 - Article
C2 - 35044418
AN - SCOPUS:85123944635
SN - 2380-6583
VL - 7
SP - 268
EP - 276
JO - JAMA Cardiology
JF - JAMA Cardiology
IS - 3
ER -